UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

May 29, 2018

 

 

Commission File Number: 001 - 38178

 

 

Zealand Pharma A/S

(Exact Name of Registrant as Specified in Its Charter)

 

 

Smedeland 36
2600 Glostrup (Copenhagen)
Denmark

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F x          Form 40-F o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  o

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  o

 

Furnished as Exhibit 99.1 to this Report on Form 6-K is a company announcement of Zealand Pharma A/S or the Company, dated May 28, 2018, announcing the completion of the second and pivotal Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia

 

 

 


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

Zealand Pharma A/S

 

 

 

By:

/s/ Mats Blom

 

 

 

 

 

Name:

Mats Blom

 

 

Title:

Chief Financial Officer

 

Date: May 29, 2018

 

2


 

EXHIBIT INDEX

 

Exhibit
No.

 

Description

 

 

 

99.1

 

Company announcement dated May 28, 2018

 

3

Zealand Pharma AS (PK) (USOTC:ZLDPF)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Zealand Pharma AS (PK) Charts.
Zealand Pharma AS (PK) (USOTC:ZLDPF)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Zealand Pharma AS (PK) Charts.